Croda expands lipid production

Published: 1-Feb-2003


Croda Healthcare is to expand significantly lipid production at its Leek site in the UK. The planned development will take place over the next 12-18 months and will double manufacturing capacity. Extensive investment in purpose-built pharmaceutical facilities has already taken place at this site, where Croda has recently commissioned a GMP API (active pharmaceutical ingredient) Super Critical CO2 plant to produce lipids with greater than 95% purity.

'We have seen strong growth in global demand for our marine and plant lipid concentrates, particularly omega-3 & 6 PUFAs for dietary supplements. There is great interest in our condition-specific products, such as the Incromega 500 series, which are supported by clinical data,' said Dr Keith Layden, md – healthcare & personal care, Croda Chemicals Europe.

You may also like